In the Specification:

At page 86, please replace page 86 with the page 86 that is attached hereto.

In the Figures:

Please replace the formal drawings that were filed on November 20, 2001 with the formal drawings that are attached hereto.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 18-1945, under Order No. JHUC-P04-010 from which the undersigned is authorized to draw.

Dated: November 8, 2004

Respectfully submitted,

By _____

David P. Halstead, Ph.D.
Registration No.: 44,735
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

Table 1. Effects of synthetic and plant-derived compounds on cholesterol homeostasis.

A. Cholesterol Biosynthesis Assay

| | Control | AY9944 (μM) | | | Triparanol (μM) | | | Jervine (μM) | | | Cyclopamine (μM) | | | Tomatidine (μM) | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | 0.25 | 0.5 | 1.0 | 0.25 | 0.5 | 1.0 | 1.25 | 2.5 | 5.0 | 1.25 | 2.5 | 5.0 | 1.25 | 2.5 | 5.0 |
| Total Sterols (μg/mg protein) | 9.6 | 7.6 | 8.3 | 8.3 | 4.1 | 5.1 | 3.1 | 8.8 | 8.4 | 10 | 8.4 | 8.5 | 8.3 | 7.8 | 7.8 | 5.6 |
| Percent Sterols | | | | | | | | | | | | | | | | |
| Cholesterol | 95 | 30 | 33 | 34 | 56 | 45 | 51 | 90 | 90 | 88 | 87 | 76 | 68 | 54 | 42 | 32 |
| Non-Cholesterol Sterols | | | | | | | | | | | | | | | | |
| 1. C27 Sterols | | | | | | | | | | | | | | | | |
| a. Desmosterol | 1.9 | | | | 9.1 | 8.7 | 6.7 | 2.5 | 2.4 | 2.7 | 4.2 | 7.1 | 11 | | | |
| b. 7 Dehydrodesmosterol | | 3.5 | 3.0 | 1.9 | 6.0 | 4.1 | 2.9 | | | | | | 0.8 | 0.8 | 0.8 | 0.5 |
| c. Cholesta-7,24-dien-3β-ol | | 1.8 | 1.9 | 1.6 | 3.1 | 2.4 | 2.6 | | 0.5 | 0.5 | 0.6 | 0.9 | 1.6 | 0.9 | 0.9 | 0.7 |
| d. Zymosterol | | | | | 9.3 | 27 | 23 | 1.7 | 2.0 | 2.3 | 2.3 | 4.5 | 4.7 | | | |
| e. Cholesta-8(14)-en-3β-ol | | 9.7 | 14 | 20 | 9.1 | 8.7 | 7.3 | 1.0 | 1.7 | 2.3 | 0.9 | 2.5 | 2.7 | 6.7 | 8.9 | 8.7 |
| f. 7 Dehydrocholesterol | | 50 | 36 | 16 | | | | 1.5 | 1.4 | 1.3 | 2.4 | 4.2 | 6.3 | 19 | 14 | 9.8 |
| g. Lathosterol | 1.3 | 6.2 | 7.3 | 7.9 | | | | | | | | | | 4.9 | 4.7 | 3.6 |
| h. C27 Sterol 1 (mw 384) | | | | 5.3 | | | | | | | | | | 7.0 | 13 | 20 |
| I. C27 Sterol 2 (mw 382) | | | | 6.0 | | | | | | | | | | | 4.1 | 4.7 |
| j. C27 Oxysterol 1 (mw 400) | | | | | | | | | | | | | | 1.0 | 2.4 | 4.5 |
| k. C27 Oxysterol 2 (mw 400) | | | | | | | | | | | | | | 2.0 | 5.0 | 11 |
| 2. C28 Sterols | 0.7 | | 1.1 | 2.6 | 4.4 | 2.6 | 1.5 | 1.2 | 0.7 | 0.7 | 1.2 | 1.3 | 1.8 | | | 1.6 |
| 3. C29 Sterols | 1 | | 3.3 | 4.6 | 7.8 | 8.1 | 5.5 | 0.8 | 0.8 | 1.6 | 0.7 | 1.2 | 3.1 | | | 3.1 |

B. Cholesterol Esterification Assay

| Percent Inhibition (incorporation of label into cholesteryl ester*) | AY9944 (μM) | | | Triparanol (μM) | | | Jervine (μM) | | | Cyclopamine (μM) | | | Tomatidine (μM) | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 2.5 | 5.0 | 10 | 2.5 | 5.0 | 10 | 2.5 | 5.0 | 10 | 2.5 | 5.0 | 10 | 2.5 | 5.0 | 10 |
| $^{3}$H-Cholesterol | 39 | 56 | 68 | 49 | 57 | 79 | 24 | 44 | 50 | 48 | 67 | 79 | 31 | 33 | 39 |
| $^{14}$C-Oleic Acid | 20 | 35 | 51 | 54 | 65 | 81 | 28 | 36 | 49 | 45 | 62 | 74 | 30 | 64 | 52 |

* The percent of label taken up that was converted to cholesteryl ester was 8%/ hour for $^{3}$H-cholesterol and 3.6%/hour for $^{14}$C-oleic acid